PolyPid (NASDAQ:PYPD) Now Covered by Analysts at Craig Hallum

Craig Hallum assumed coverage on shares of PolyPid (NASDAQ:PYPD) in a research report report published on Monday, Benzinga reports. The brokerage issued a buy rating and a $10.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of PolyPid in a report on Wednesday, October 2nd.

PolyPid Stock Performance

PYPD traded up $0.04 during midday trading on Monday, reaching $3.37. The company had a trading volume of 310 shares, compared to its average volume of 6,172. The business has a 50-day moving average of $3.48 and a two-hundred day moving average of $3.87. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. PolyPid has a 1 year low of $2.95 and a 1 year high of $9.20.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, August 14th. The company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.26. On average, equities research analysts predict that PolyPid will post -4.39 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PolyPid stock. Rosalind Advisors Inc. grew its holdings in PolyPid Ltd. (NASDAQ:PYPD) by 62.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 679,168 shares of the company’s stock after buying an additional 262,368 shares during the period. PolyPid makes up 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 18th largest holding. Rosalind Advisors Inc. owned approximately 14.16% of PolyPid worth $2,336,000 as of its most recent SEC filing. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.